Holen Sie sich die Stockscreener-App
2.00
12.02%
0.17
Schlusskurs vom Vortag:
$1.83
Offen:
$1.83
24-Stunden-Volumen:
89,769
Relative Volume:
0.52
Marktkapitalisierung:
$21.21M
Einnahmen:
$1.85M
Nettoeinkommen (Verlust:
$-5.26M
KGV:
-2.116
EPS:
-0.9452
Netto-Cashflow:
-
1W Leistung:
+15.17%
1M Leistung:
-26.79%
6M Leistung:
+0.00%
1J Leistung:
+0.00%
1-Tages-Spanne:
$1.83
$2.08
1-Wochen-Bereich:
$1.7005
$2.08
52-Wochen-Spanne:
$1.51
$14.09
20 20 Biolabs Inc Stock (AIDX) Company Profile
Firmenname
20 20 Biolabs Inc
Sektor
Branche
Telefon
-
Adresse
-
Compare AIDX vs ABT, SYK, MDT, BSX, EW
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
AIDX
20 20 Biolabs Inc
|
2.05 | 18.94M | 1.85M | -5.26M | 0 | -0.9452 |
ABT
Abbott Laboratories
|
102.17 | 178.75B | 44.33B | 6.50B | 7.40B | 3.717 |
SYK
Stryker Corp
|
332.34 | 126.97B | 25.12B | 3.25B | 4.28B | 8.3984 |
MDT
Medtronic Plc
|
86.28 | 111.22B | 35.48B | 4.64B | 5.41B | 3.582 |
BSX
Boston Scientific Corp
|
62.59 | 93.36B | 20.08B | 2.89B | 3.66B | 1.9391 |
EW
Edwards Lifesciences Corp
|
81.06 | 46.73B | 6.07B | 1.06B | 1.34B | 1.8063 |
20 20 Biolabs Inc Aktie (AIDX) Neueste Nachrichten
AIDX : 20/20 Biolabs Inc. Key Company Metrics & Non-finance Metrics - Zacks Investment Research
20/20 Biolabs, Inc. (AIDX) stock price, news, quote and history - Yahoo Finance Singapore
AIDX: 20/20 Biolabs Inc.Financial Overview - Zacks Investment Research
20/20 BioLabs (AIDX) Reports 17% Revenue Growth in 2025 and Eyes Significant Expansion in 2026 with AI-Powered Cancer Detection Blood Tests - Minichart
20/20 BioLabs (AIDX) grows 2025 revenue 17% and narrows annual net loss - Stock Titan
20/20 Biolabs 10-K: Revenues $2.05M, Net Loss $(3.74)M - TradingView
20/20 Biolabs (NASDAQ: AIDX) outlines AI blood tests, longevity and growth - Stock Titan
20/20 BioLabs Reports Full Year 2025 Financial Results and Recent Operational Progress - The Manila Times
Maryland funds firefighter cancer tests as 20/20 lifts margins - Stock Titan
AIDX | 20/20 Biolabs, Inc. Common Institutional Ownership - Quiver Quantitative
20/20 BioLabs announces grants for Maryland fire departments to procure OneTest - TipRanks
Maryland Fire Departments Awarded $520,000 for Cancer Screenings using 20/20 BioLabs’ OneTest ™ Multi-Cancer Early Detection Blood Test - The Manila Times
Maryland funds cancer blood tests for more than 1,400 firefighters - Stock Titan
20/20 BioLabs licenses kidney disease prediction technology from ROKIT Healthcare - MSN
Maryland Fire Departments Awarded $520,000 for Cancer Screenings using 20/20 BioLabs' OneTest Multi-Cancer Early Detection Blood Test - Bitget
20/20 BioLabs licenses kidney disease prediction technology By Investing.com - Investing.com Canada
What's going on with 20/20 Biolabs stock? - MSN
12 Health Care Stocks Moving In Tuesday's After-Market Session - Benzinga
20/20 BioLabs enters exclusive technology license, access agreement with Rokit - TipRanks
What's Going On With 20/20 Biolabs Stock? - Benzinga
20/20 Biolabs Faces Decline Amid Market Rut - timothysykes.com
20/20 BioLabs licenses kidney disease prediction technology - Investing.com
20/20 Biolabs shares are trading lower after ... - Benzinga
20/20 BioLabs Announces Exclusive U.S. License Agreement with ROKIT Healthcare to Integrate Advanced CKD Prediction Technology into Its Longevity Test Program - The Manila Times
20/20 BioLabs Announces Exclusive U.S. License Agreement - GlobeNewswire
What is the current Price Target and Forecast for 20/20 Biolabs Inc. (AIDX) - Zacks Investment Research
What date does 20/20 Biolabs Inc.'s (AIDX) report EarningsEarnings Calendar & Announcement - Zacks Investment Research
AIDX Stock Price, News & Analysis - Stock Titan
Debt to equity ratio of 20/20 Biolabs, Inc. – NASDAQ:AIDX - TradingView
20/20 Biolabs Inc. (AIDX) Total Long Term Debt (Quarterly) - Zacks Investment Research
20/20 Biolabs Inc. (AIDX) Return On Assets (TTM) - Zacks Investment Research
20/20 Biolabs Inc. (AIDX) Total Expenses (TTM) - zacks.com
20/20 Biolabs Inc. (AIDX) Price Book Value - Zacks Investment Research
Cash per share of 20/20 Biolabs, Inc. – NASDAQ:AIDX - TradingView
Michael A. Ross Net Worth (2026) - GuruFocus
Michael Saul Lebowitz Net Worth (2026) - GuruFocus
Jonathan M Cohen Net Worth (2026) - GuruFocus
Prasanth Reddy Net Worth (2026) - GuruFocus
Jiming Zhou Net Worth (2026) - GuruFocus
20/20 BioLabs Highlights Advantages of its Patented Protein Biomarker Technology for Multi-Cancer Early Detection in Light of Recent Studies - Sahm
20/20 Biolabs, Inc. Revenue Breakdown – NASDAQ:AIDX - TradingView
Analysts Offer Insights on Healthcare Companies: 20/20 Biolabs, Inc. (AIDX) and Biogen (BIIB) - The Globe and Mail
20/20 BioLabs provides update on protein biomarket technology for MCED - TipRanks
Blood test using proteins aims to catch cancer years earlier than DNA screens - Stock Titan
Jonathan Cohen Discloses Investment at 20/20 Biolabs with 16.8% Stake - TradingView
Full Succeed (AIDX) owns 6.3% — 651,465 shares disclosed in Schedule 13G - Stock Titan
20/20 Biolabs (AIDX) CEO awarded 352,936-share stock option grant - Stock Titan
20/20 Biolabs Inc. (AIDX) Revenue (Quarterly) Yoy Growth - Zacks Investment Research
20/20 Biolabs (AIDX) 10K Form and SEC Filings 2026 - MarketBeat
20/20 Biolabs Inc. (AIDX) Free Cash Flow (TTM) - Zacks Investment Research
12 Health Care Stocks Moving In Wednesday's Pre-Market Session - Benzinga
Finanzdaten der 20 20 Biolabs Inc-Aktie (AIDX)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.25%
0.38%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):